Moolec Science (Moolec Science) EBIT : $-7.12 Mil (TTM As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Moolec Science EBIT?

Moolec Science's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-1.92 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.12 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Moolec Science's annualized ROC % for the quarter that ended in Dec. 2023 was -28.89%. Moolec Science's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -528.73%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Moolec Science's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -13.81%.

Moolec Science EBIT Historical Data

The historical data trend for Moolec Science's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moolec Science EBIT Chart

Moolec Science Annual Data

Trend

Jun21

Jun22

Jun23

EBIT

-4.53

-51.86

Moolec Science Quarterly Data
	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial					-47.96	-0.45	-3.05	-1.71	-1.92

Competitive Comparison of Moolec Science's EBIT

For the Biotechnology subindustry, Moolec Science's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moolec Science's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moolec Science's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Moolec Science's EV-to-EBIT falls into.

Moolec Science EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.12 Mil.

Moolec Science (NAS:MLEC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Moolec Science's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-7.172 * ( 1 - 11.68% )	/	( (23.072	+	20.776)	/ 2 )
=	-6.3343104	/	21.924
=	-28.89 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	22.492	-	8.736	-	( 0.854	-	max(0, 12.513	-	3.197	+	0.854	))
=	23.072

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	21.321	-	5.276	-	( 1.834	-	max(0, 8.281	-	3.55	+	1.834	))
=	20.776

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Moolec Science's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-7.664	/	( ( (1.605 + max(-8.956, 0))	+	(1.294 + max(-5.09, 0)) )	/	2 )
=	-7.664	/	( ( 1.605	+	1.294 )	/	2 )
=	-7.664	/	1.4495
=	-528.73 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.503	+	0.39	+	0.143)	-	(8.736	+	0.499	+	0.757)
=	-8.956

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.285	+	0.502	+	0.014)	-	(5.276	+	0	+	0.615)
=	-5.09

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Moolec Science's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-7.121	/	51.578
	=	-13.81 %

Moolec Science EBIT Related Terms

Thank you for viewing the detailed overview of Moolec Science's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Moolec Science (Moolec Science) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moolec Science SA (NAS:MLEC) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

17, Boulevard F.W. Raiffeisen, Luxembourg, LUX, L-2411

Website

https://www.moolecscience.com

Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system.